Med Oncol. 2012 Jun;29(2):1253-4. doi: 10.1007/s12032-011-9878-z.
We retrospectively evaluated the efficacy and toxicity of docetaxel and carboplatin in patients with platinum and paclitaxel-pretreated recurrent ovarian, fallopian tube, and peritoneal cancer. Forty-two women (38 with ovarian cancer, 1 with fallopian tube cancer, 3 with peritoneal cancer) whose cancer had progressed within 12 months of their last treatment with both a platinum agent and paclitaxel were treated with docetaxel (70 mg/m(2), day 1) and carboplatin (area under the curve of 4-6, day 1). Thirty-four patients had measurable disease. The objective response rate was 23% within 0-6 months of the progression-free interval, 50% within 6-12 months, and 32% (11 of 34 patients) for both groups. The median time to tumor progression was 28, 49, 34 weeks, and the median overall survival time was 94, 224, 111 weeks, respectively. The most common toxicity was grade 3/4 neutropenia (98% of patients), with 15 episodes (8.4% of courses) of neutropenic fever. The main nonhematologic toxicity was hypersensitivity; 7 patients (17%) required discontinuation of the therapy. The results of our study indicate that the combination of docetaxel and carboplatin is effective against recurrent ovarian, fallopian tube, and peritoneal cancer with progression-free interval of 6-12 months from previous treatment by paclitaxel and platinum. On the other hand, single-agent chemotherapy would be better than this regimen considering its low response rate and severe hematological toxicity for patients with progression-free interval less than 6 months.
我们回顾性评估了多西紫杉醇和卡铂在铂类和紫杉醇预处理的复发性卵巢、输卵管和腹膜癌患者中的疗效和毒性。42 名女性（38 例卵巢癌，1 例输卵管癌，3 例腹膜癌）在最后一次使用铂类和紫杉醇治疗后 12 个月内癌症进展，接受多西紫杉醇（70mg/m2，第 1 天）和卡铂（曲线下面积 4-6，第 1 天）治疗。34 名患者有可测量的疾病。无进展间隔 0-6 个月时的客观缓解率为 23%，6-12 个月时为 50%，两组均为 32%（34 名患者中的 11 名）。肿瘤进展的中位时间分别为 28、49、34 周，中位总生存期分别为 94、224、111 周。最常见的毒性是 3/4 级中性粒细胞减少症（98%的患者），中性粒细胞减少症发热 15 次（8.4%的疗程）。主要的非血液学毒性是过敏反应；7 名患者（17%）需要停止治疗。我们的研究结果表明，多西紫杉醇和卡铂联合治疗紫杉醇和铂类治疗后 6-12 个月无进展间隔的复发性卵巢、输卵管和腹膜癌是有效的。另一方面，对于无进展间隔小于 6 个月的患者，由于其反应率低且血液学毒性严重，单药化疗可能优于该方案。
